NEW YORK (TheStreet) -- Dynavax was among several stocks trading near $5poised to surge on heavy volume after clinical data showed its experimental hepatitis B vaccine showed promise in treating chronic kidney disease.
Dynavax said Phase II trials "demonstrate HEPLISAV 's immunogenicity and rapid protection in patients with chronic kidney disease." Dynavax said results showed that two doses of HEPLISAV protected 100% of the dialysis and pre-dialysis patients measured at week 24 in the Phase II study.
After closing at $1.45 Wednesday, Dynavax shares rallied by 35 cents, or 24.1%, to $1.80 in Thursday's premarket session. The 50-day average daily volume for Dynavax is 326,000, according to the Nasdaq.
CompuCredit Holdings (CCRT) was also indicated to trade higher on increased volume after the financial services said it will hold a modified Dutch auction tender offer for both debt and stock. CompuCredit said the offer is to purchase up to $100 million of its outstanding 3.625% convertible senior notes, as well as shares of outstanding common stock at a purchase price of $7 per share if there is money left over from the note purchase.CompuCredit shares closed at $5.56 Wednesday and rose nearly 17% in the after-market session to $6.50. The 50-day average daily volume for CompuCredit is 100,000. On the other hand, Santarus (SNTS) should lose ground on above-average volume after the U.S. District Court for the District of Delaware ruled that five patents covering Santarus' prescription products are invalid due to obviousness. Par Pharmaceutical (PRX) brought the lawsuit against Santarus. Santarus shares were plummeting by $2.28, or 42.5%, to $3.08 in Thursday's premarket session. The 50-day average daily volume for Santarus is 437,000. The Princton Review (REVU) was also poised to trade lower after the company announced an offering of 14 million common shares. After finishing Wednesday's session at $3.47, the stock fell 6.9% to $3.23 in late trading. The 50-day average daily volume for the Princeton Review is 63,000. -- Written by Robert Holmes in Boston. Check out all of Thursday's high-volume, under-$5 stocks at the Dollar Store. View the Dollar Store portfolio on StockPickr. Follow Robert Holmes on Twitter and become a fan of TheStreet.com on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV